Skip to Main Content

Vigil Neuroscience has revealed the first condition that it will target: a rare, genetic neurodegenerative disorder called ALSP, or adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.

The Cambridge, Mass.-based company, which bought the rights to all its current drug candidates from Amgen, also announced a $90 million series B financing round on Wednesday.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment